CPT15 - NSAIDs Flashcards
1
Q
4 features of eicosanoid synthesis
Arachidonic Acid
Endoperoxides
COX-1 Enzyme
COX-2 Enzyme
A
- ) Arachidonic Acid - produced from phospholipids
- derived primarily from dietary linoleic acid
- enzyme involved is phospholipase A2
- found throughout the body esp muscle, brain and liver - ) Endoperoxides - unstable intermediates
- arachidonic acid –> endoperoxides –> prostanoids
- COX enzymes converts them into prostanoids - ) COX-1 Enzyme
- constitutively active across most tissues - ) COX-2 Enzyme
- inducible mostly in chronic inflammation
- increased activity in the brain, kidneys, and bone
- has a larger substrate binding site than COX-1 so some drugs can be selective to COX-2
2
Q
3 types of prostanoids
Prostaglandins
Prostacyclin
Thromboxane A2
PGI2 and TXA2 Balance
A
- ) Prostaglandins - PGE2, PGF2-alpha, PGD2
- involved in pain, pyrexia, and inflammation
- action is often enhanced by local autacoids such as bradykinin and histamine - ) Prostacyclin - PGI2
- vasodilator and inhibits platelet aggregation
- it is cytoprotective for the CVS - ) Thromboxane A2 - TXA2
- vasoconstrictor and activates platelet aggregation
- it is generally bad for the CVS - ) PGI2 and TXA2 Balance - opposing vascular effects
- balance for haemodynamic and thrombogenic control
- imbalance –> hypertension, MI, stroke etc.
3
Q
6 features of NSAIDs
Examples x6 Mechanism COX-2 Selectivity Usage x6 Caution x3 Side Effects (IGRAB)
A
- ) Examples - aspirin, ibuprofen, naproxen, diclofenac
- celecoxib and etoricoxib are COX-2 selective - ) Mechanism - competitive inhibition of COX enzymes
- ↓prostaglandin, prostacylin and thromboxane synthesis - ) COX-2 Selectivity - aspirin is least selective
- less GI ADRs but similar renal ADRs
- doesn’t inhibit prostacyclins, leaving TXA2 unopposed which can be bad for the CVS - ) Usage - pain, fever, inflammation
- arthritis, menorrhagia, opioid sparing
- long term usage could be prescribed with a PPI (omeprazole) - ) Caution
- asthma: can cause bronchospasm in 10-20% of patient with asthma
- heart failure: can cause fluid retention exacerbating heart failure
- GI risk factors: elderly, smoking, alcohol, H. pylori
- GI diseases: peptic ulcers, IBD
- with other drugs: PPI, anticoagulants, ACEi (also ↓GFR) - ) Side Effects - IGRAB
- Interactions w/ other medication e.g. warfarin
- Gastric ulceration, Renal impairment
- Asthma sensitivity, Bleeding risk
- fluid retention
4
Q
3 functions of NSAIDs
A
- ) Analgesia - local peripheral action at site of pain
- ↓PGE2 synthesis in DH –> ↓neurotransmitter release -> ↓excitability of neurones in pain relay pathway
- full analgesia occurs after several days of dosing - ) Anti-Inflammatory - inhibits prostaglandins
- leads to ↓inflammation (vasodilation, swelling)
- symptomatic relief, little effect on underlying condition - ) Antipyretic - inhibits COX-2 in the hypothalamus
- prostaglandins can act on the thermoregulatory centre and increase the temp set point to cause a fever
- PGE2 can be stimulated by pyrogens (cytokines)
- therefore, ↓PGE2 leads to reduction in temperature
5
Q
2 main side effects of NSAIDs
GI ADRs
Renal ADRs
A
- ) GI ADRs - nausea, peptic ulcers, bleeding, perforation
- ↓mucus and ↓HCO3 –> ↑acid secretion
- ↓mucosal blood floow –> hypoxia and cytotoxicity
- exacerbation of IBD - ) Renal ADRs - ↓GFR and ↓renal blood flow
- prevents vasodilation of AA (↓PGE2/PGI2)
- ↑sodium absorption in CD (inhibition of prostaglandins)
- ADRs in underlying CKD and heart failure
6
Q
3 main drug interactions with NSAIDs (protein-binding)
A
- ) Sulfonylureas - can lead to hypoglycaemia
- ) Methotrexate - hepatotoxicity, leukopenia, RA
- ) Warfarin - increases risk of bleeding